PolyPeptide Group AG (0AAJ.L)

CHF 16.06

(3.48%)

Total Liabilities Summary of PolyPeptide Group AG

PolyPeptide Group AG's latest annual total liabilities in 2023 was 307.86 Million EUR , up 99.77% from previous year.
PolyPeptide Group AG's latest quarterly total liabilities in 2023 FY was 307.86 Million EUR , up 99.77% from previous quarter.
PolyPeptide Group AG reported annual total liabilities of 154.1 Million EUR in 2022, down -11.37% from previous year.
PolyPeptide Group AG reported annual total liabilities of 173.86 Million EUR in 2021, down -12.33% from previous year.
PolyPeptide Group AG reported quarterly total liabilities of 307.86 Million EUR for 2023 FY, up 99.77% from previous quarter.
PolyPeptide Group AG reported quarterly total liabilities of 307.86 Million EUR for 2023 Q4, down 0.0% from previous quarter.

Annual Total Liabilities Chart of PolyPeptide Group AG (2023 - 2018)

Historical Annual Total Liabilities of PolyPeptide Group AG (2023 - 2018)

Year	Total Liabilities	Total Liabilities Growth
2023	307.86 Million EUR	99.77%
2022	154.1 Million EUR	-11.37%
2021	173.86 Million EUR	-12.33%
2020	198.31 Million EUR	27.35%
2019	155.72 Million EUR	14.38%
2018	136.15 Million EUR	0.0%

Year	Total Liabilities	Total Liabilities Growth
2023 Q2	204.8 Million EUR	0.0%
2023 FY	307.86 Million EUR	99.77%
2023 Q4	307.86 Million EUR	0.0%
2022 Q4	154.1 Million EUR	0.0%
2022 Q2	151.94 Million EUR	0.0%
2022 FY	154.1 Million EUR	-11.37%
2021 Q4	173.86 Million EUR	0.0%
2021 Q2	186.26 Million EUR	0.0%
2021 FY	173.86 Million EUR	-12.33%
2020 FY	198.31 Million EUR	27.35%
2020 Q4	198.31 Million EUR	0.0%
2019 Q4	38.93 Million EUR	0.0%
2019 Q3	38.93 Million EUR	0.0%
2019 Q2	38.93 Million EUR	0.0%
2019 Q1	38.93 Million EUR	14.38%
2019 FY	155.72 Million EUR	14.38%
2018 Q2	34.03 Million EUR	0.0%
2018 Q4	34.03 Million EUR	0.0%
2018 Q3	34.03 Million EUR	0.0%
2018 FY	136.15 Million EUR	0.0%
2018 Q1	34.03 Million EUR	0.0%

Peer Total Liabilities Comparison of PolyPeptide Group AG

Name	Total Liabilities	Total Liabilities Difference
Kuros Biosciences AG	19.19 Million CHF	-1503.954%